BioForce NanoScience Holdings Appoints Interim CEO and Advisory Board

What Happened

• BioForce NanoScience Holdings, Inc. filed an 8-K (Item 8.01) reporting changes to its management and governance. On June 17, 2026, the Board appointed Richard Kaiser as interim Chief Executive Officer. Mr. Kaiser remains the Company’s Chief Financial Officer, Secretary and a director and has served as an officer/director since July 1, 2013.
• The company established an Advisory Board on May 19, 2026 and appointed Stuart J. Yarbrough and Edward J. Mathias to three‑year advisory terms ending May 19, 2029.
• On May 19, 2026 the Board also named Scott Mager as General Counsel under a three‑year contract; on June 15, 2026 Mr. Mager was appointed to the Board as a director. The filing states there are no arrangements or related‑party transactions requiring disclosure under Item 404 for Mr. Mager.

Key Details

• Interim CEO: Richard Kaiser appointed June 17, 2026; has been with BFNH since July 1, 2013 and retains CFO and Secretary roles.
• Advisory Board: Stuart J. Yarbrough and Edward J. Mathias; terms run May 19, 2026 to May 19, 2029.
• General Counsel/Director: Scott Mager appointed General Counsel May 19, 2026 (3‑year contract) and director June 15, 2026.
• Filing notes no related‑party transactions or special arrangements disclosed for the new director; includes standard forward‑looking statement cautionary language.

Why It Matters

• These appointments change BFNH’s leadership and advisory composition—important governance information for investors tracking management continuity and oversight.
• The filing provides names, dates and term lengths but does not include material financial terms beyond a three‑year General Counsel contract or disclose compensation for advisory board members; investors should look for future filings if compensation, strategic plans, or material transactions are announced.